About gilead sciences inc. - GILD
GILD At a Glance
| Phone | 1-650-574-3000 | Revenue | 29.45B | |
| Industry | Biotechnology | Net Income | 8.51B | |
| Sector | Health Technology | 2025 Sales Growth | 2.51% | |
| Fiscal Year-end | 12 / 2026 | Employees | 17,000 | |
| View SEC Filings |
GILD Valuation
| P/E Current | 17.845 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.101 |
| Price to Sales Ratio | 5.231 |
| Price to Book Ratio | 6.709 |
| Price to Cash Flow Ratio | 15.37 |
| Enterprise Value to EBITDA | 11.65 |
| Enterprise Value to Sales | 5.769 |
| Total Debt to Enterprise Value | 0.15 |
GILD Efficiency
| Revenue/Employee | 1,732,235.294 |
| Income Per Employee | 500,588.235 |
| Receivables Turnover | 5.994 |
| Total Asset Turnover | 0.499 |
GILD Liquidity
| Current Ratio | 1.553 |
| Quick Ratio | 1.403 |
| Cash Ratio | 0.814 |
GILD Profitability
| Gross Margin | 78.844 |
| Operating Margin | 40.145 |
| Pretax Margin | 33.265 |
| Net Margin | 28.898 |
| Return on Assets | 14.422 |
| Return on Equity | 40.492 |
| Return on Total Capital | 17.639 |
| Return on Invested Capital | 18.899 |
GILD Capital Structure
| Total Debt to Total Equity | 112.501 |
| Total Debt to Total Capital | 52.941 |
| Total Debt to Total Assets | 43.273 |
| Long-Term Debt to Equity | 99.687 |
| Long-Term Debt to Total Capital | 46.912 |
Gilead Sciences Inc. in the News
Top 5 most expensive drugs for consumers
Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's the list.
Drugmakers raised prices by 6.6% on average early this year
Drugmakers raised prices an average of 6.6% at the start of 2022.
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Inside the race for a COVID-19 treatment pill
Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.
COVID-19 vaccine start-up files for IPO
The biotech startup behind the COVID-fox19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering. Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus.